Search Result

Results for "

MCAO

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adenosine Receptor (1) Adrenergic Receptor (1) Akt (5) Apoptosis (11) Autophagy (2) Bacterial (1) Bcl-2 Family (2) Calcium Channel (5) Caspase (2) COX (1) Cytochrome P450 (1) Drug Derivative (1) Epigenetic Reader Domain (2) ERK (3) Ferroptosis (3) Glutathione Peroxidase (4) GPR65 (1) Heme Oxygenase (HO) (2) Histamine Receptor (1) iGluR (4) Indoleamine 2,3-Dioxygenase (IDO) (2) Interleukin Related (1) Isotope-Labeled Compounds (1) Keap1-Nrf2 (3) mAChR (2) nAChR (1) NF-κB (4) NKCC (2) NO Synthase (1) NOD-like Receptor (NLR) (1) P2Y Receptor (1) p38 MAPK (4) PGC-1α (1) PI3K (3) Potassium Channel (4) PPAR (1) Reactive Oxygen Species (ROS) (12) Reference Standards (4) RIP kinase (1) Sigma Receptor (2) TGF-β Receptor (2) TNF Receptor (2) TRP Channel (4) VEGFR (2)
By Research Areas:	Cancer (7) Cardiovascular Disease (18) Infection (1) Inflammation/Immunology (4) Metabolic Disease (5) Neurological Disease (28)

By Targets:

Adenosine Receptor (1)

Adrenergic Receptor (1)

Akt (5)

Apoptosis (11)

Autophagy (2)

Bacterial (1)

Bcl-2 Family (2)

Calcium Channel (5)

Caspase (2)

COX (1)

Cytochrome P450 (1)

Drug Derivative (1)

Epigenetic Reader Domain (2)

ERK (3)

Ferroptosis (3)

Glutathione Peroxidase (4)

GPR65 (1)

Heme Oxygenase (HO) (2)

Histamine Receptor (1)

iGluR (4)

Indoleamine 2,3-Dioxygenase (IDO) (2)

Interleukin Related (1)

Isotope-Labeled Compounds (1)

Keap1-Nrf2 (3)

mAChR (2)

nAChR (1)

NF-κB (4)

NKCC (2)

NO Synthase (1)

NOD-like Receptor (NLR) (1)

P2Y Receptor (1)

p38 MAPK (4)

PGC-1α (1)

PI3K (3)

Potassium Channel (4)

PPAR (1)

Reactive Oxygen Species (ROS) (12)

Reference Standards (4)

RIP kinase (1)

Sigma Receptor (2)

TGF-β Receptor (2)

TNF Receptor (2)

TRP Channel (4)

VEGFR (2)

By Research Areas:

Cancer (7)

Cardiovascular Disease (18)

Infection (1)

Inflammation/Immunology (4)

Metabolic Disease (5)

Neurological Disease (28)

Inhibitors & Agonists

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-139192

Brophenexin 2 Publications Verification NMDAR/TRPM4-IN-2	iGluR TRP Channel ERK	Neurological Disease
Brophenexin (compound 8) is a potent NMDAR/TRPM4 interaction interface inhibitor. Brophenexin shows neuroprotective activity. Brophenexin prevents NMDA-induced cell death and mitochondrial dysfunction in hippocampal neurons, with an IC₅₀ of 2.1 μM. Brophenexin protects mice from MCAO-induced brain damage and NMDA-induced retinal ganglion cell loss .

HY-139192A

Brophenexin free base 2 Publications Verification NMDAR/TRPM4-IN-2 free base	iGluR TRP Channel ERK	Neurological Disease
Brophenexin free base (compound 8) is a potent NMDAR/TRPM4 interaction interface inhibitor. Brophenexin free base shows neuroprotective activity. Brophenexin free base prevents NMDA-induced cell death and mitochondrial dysfunction in hippocampal neurons, with an IC₅₀ of 2.1 μM. Brophenexin free base protects mice from MCAO-induced brain damage and NMDA-induced retinal ganglion cell loss .

HY-173142

Neuroprotective agent 7	Drug Derivative	Neurological Disease
Neuroprotective agent 7 (Compound 13) is a BBB-penetrable neuroprotective agent. Neuroprotective agent 7 has a powerful neuroprotective effect and can reduce the cerebral infarct area in the MCAO rat model. Neuroprotective agent 7 can be used in the research of diseases such as cerebral ischemia .

HY-174127

P2Y1 antagonist 3	P2Y Receptor	Neurological Disease
P2Y1 antagonist 3 (compound 36b) is a blood-brain barrier (BBB)-penetrant P2Y1 antagonist with an IC₅₀ of 0.50 μM. P2Y1 antagonist 3 exhibits protective effects in a rat middle cerebral artery occlusion (MCAO) model and demonstrates neuroprotective activity against oxidative stress by upregulating nuclear Nrf2 protein levels .

HY-159928

Neuroprotective agent 8	Reactive Oxygen Species (ROS) PGC-1α NOD-like Receptor (NLR)	Neurological Disease
Neuroprotective agent 8 (compound AA-9) is an oral active neuroprotective agent by anti-oxidative stress and anti-inflammation. Neuroprotective agent 8 activates PGC-1α and inhibits NLRP3 in the rat MCAO ischemic stroke model .

HY-176347S

Alpha Feto Protein, Arg-13C6,15N4, Lys-13C6,15N2	Isotope-Labeled Compounds	Cancer
Alpha Feto Protein, Arg- ¹³C₃₆, ¹⁵N₄, Lys- ¹³C₆, ¹⁵N₂ is the ¹³C- and ¹⁵N-labeled Alpha Feto Protein.

HY-127022A

Anisodine hydrobromide Daturamine hydrobromide; α-Hydroxyscopolamine hydrobromide	mAChR Calcium Channel Reactive Oxygen Species (ROS)	Neurological Disease
Anisodine (Daturamine) hydrobromide is a neuroprotective compound that reduces exacerbated M1, M2, M4, and M5 receptor expression in brain tissues under hypoxia/reoxygenation conditions. Anisodine hydrobromide inhibits calcium ion influx and reactive oxygen species (ROS)levels. Anisodine hydrobromide leads to decreased aspartate levels during hypoxia .

HY-123654

L-796449	PPAR	Neurological Disease
L-796449 is a potent PPARγ agonist. L-796449 shows neuroprotective. L-796449 has the potential for the research of stroke .

HY-127022

Anisodine Daturamine; α-Hydroxyscopolamine	mAChR Calcium Channel Reactive Oxygen Species (ROS)	Neurological Disease
Anisodine (Daturamine) is a neuroprotective compound that reduces exacerbated M1, M2, M4, and M5 receptor expression in brain tissues under hypoxia/reoxygenation conditions. Anisodine inhibits calcium ion influx and reactive oxygen species (ROS)levels. Anisodine leads to decreased aspartate levels during hypoxia .

HY-172455

TREK inhibitor-3	Potassium Channel	Neurological Disease
TREK inhibitor-3 (Cpd8l) is a selective and BBB-permeable TREK-1 inhibitor with an IC₅₀ of 0.81 μM. TREK inhibitor-3 has neuroprotective effects, which can significantly reduce the death of cortical neurons induced by oxygen-glucose deprivation/reoxygenation (OGD/R) and improve brain injury in mice models of middle cerebral artery occlusion/reperfusion (MCAO/R). TREK inhibitor-3 can be used in the research of ischemic stroke .

HY-N8931

Monomethyl lithospermate Lithospermic acid monomethyl ester	Akt	Neurological Disease
Monomethyl lithospermate activates the PI3K/AKT pathway, which plays a protective role in nerve injury. Monomethyl lithospermate can improve the survival ability of SHSY-5Y cells, inhibit the breakdown of mitochondrial membrane potential (MMOP) and inhibit cell apoptosis. Monomethyl lithospermate also reduced the level of oxidative stress in the brain tissue of rats with middle artery occlusion (MCAO) and improved nerve damage in rats with ischemic stroke (IS) .

HY-108801A

Aflibercept (VEGF Trap) 1 Publications Verification	VEGFR	Cardiovascular Disease Metabolic Disease Cancer
Aflibercept (VEGF Trap) is a soluble decoy VEGFR constructed by fusing the Ig domains of VEGFR1 and VEGFR2 with the Fc region of human IgG1. Aflibercept inhibits VEGF signaling by reducing VEGF-regulated processes. Aflibercept can be used for thr research of age-related macular degeneration (AMD) and cardiovascular disease .

HY-108801

Aflibercept VEGF Trap; VEGF-TRAPR1R2; VEGF-trapR1	VEGFR	Cardiovascular Disease Metabolic Disease Cancer
Aflibercept (VEGF Trap) is a soluble decoy VEGFR constructed by fusing the Ig domains of VEGFR1 and VEGFR2 with the Fc region of human IgG1. Aflibercept inhibits VEGF signaling by reducing VEGF-regulated processes. Aflibercept can be used for thr research of age-related macular degeneration (AMD) and cardiovascular disease .

HY-126049

(S)-Oxiracetam (S)-(-)-Oxiracetam; (S)-ISF2522	Apoptosis	Neurological Disease
(S)-oxiracetam (S-ORC) is an inhibitor targeting apoptosis. S-ORC reduces brain infarct size and lessens neurological dysfunction in middle cerebral artery occlusion/reperfusion (MCAO/R) models. S-ORC prevents neuronal apoptosis via activating PI3K/Akt/GSK3β signaling pathway via α7 nAChR after ischemic stroke. S-ORC can prevent neuronal death after ischemic stroke .

HY-168770

Cl-Necrostatin-1	RIP kinase TNF Receptor Apoptosis	Cardiovascular Disease
Cl-Necrostatin-1 is a RIPK1 inhibitor. Cl-Necrostatin-1 can also inhibit TNF-α-induced necroptosis in Jurkat cells deficient in Fas-associated death domain protein (FADD; EC₅₀ = 180 nM), a modification that prevents caspase activation in response to death-domain receptor signaling. Cl-Necrostatin-1 can also reduce infarct size in a mouse model of middle cerebral artery occlusion (MCAO). Cl-Necrostatin-1 is used for research in cardiovascular and cerebrovascular diseases .

HY-175032

ATF3-IN-1	Ferroptosis Epigenetic Reader Domain Reactive Oxygen Species (ROS) Glutathione Peroxidase	Cardiovascular Disease Neurological Disease
ATF3-IN-1 is a ferroptosis and ATF3 inhibitor. ATF3-IN-1 inhibits oxidative stress and ferroptosis through the ATF3/SLC7A11/GPX4 pathway, exerting anti-ischemic stroke effects. ATF3-IN-1 can attenuate ischemia/reperfusion (I/R) injury and improve neuronal survival. ATF3-IN-1 has neuroprotective effects and can be used to study ischemic stroke .

HY-155997

Anti-inflammatory agent 56	COX	Inflammation/Immunology
Anti-inflammatory agent 56 (Compound 9) is a selective COX-2 inhibitor (IC₅₀: 0.54 μM). Anti-inflammatory agent 56 has anti-oxidant and anti-inflammatory effects. Anti-inflammatory agent 56 inhibits oxidative stress induced cell death. Anti-inflammatory agent 56 inhibits oxidative stress and neuroinflammation by inhibiting Keap1, COX-2 and iNOS. Anti-inflammatory agent 56 has low acute toxicity in mice (LD₅₀: 1000 mg/kg) .

HY-B1216

Oxeladin citrate	Sigma Receptor	Cardiovascular Disease Others Neurological Disease
Oxeladin citrate is an orally active and brain-penetrant cough suppressant as well as a selective sigma 1 receptor agonist (K_i = 25 nM). Oxeladin can be used for pulmonary diseases and stroke research .

HY-18939

N6-Cyclohexyladenosine 2 Publications Verification CHA	Adenosine Receptor PI3K Akt Epigenetic Reader Domain	Neurological Disease Cancer
N6-Cyclohexyladenosine is a selective adenosine A1 receptor agonist (EC₅₀ = 8.2 nM). N6-Cyclohexyladenosine enhances the activation of the PI3K/Akt/CREB/BDNF axis. N6-Cyclohexyladenosine promotes remyelination, induces sleep, and improves 3-NP-induced Huntington's disease. N6-Cyclohexyladenosine can be used in liver cancer research .

HY-B1216R

Oxeladin citrate (Standard)	Reference Standards Sigma Receptor	Cardiovascular Disease Others Neurological Disease
Oxeladin (citrate) (Standard) is the analytical standard of Oxeladin (citrate). This product is intended for research and analytical applications. Oxeladin citrate is an orally active and brain-penetrant cough suppressant as well as a selective sigma 1 receptor agonist (Ki = 25 nM). Oxeladin can be used for pulmonary diseases and stroke research .

HY-161104

Kv2.1-IN-1 1 Publications Verification	Potassium Channel Apoptosis	Cardiovascular Disease Neurological Disease
Kv2.1-IN-1 is an orally active and blood-brain barrier penetrant Kv2.1 inhibitor with an IC₅₀ of 0.07 μM. Kv2.1-IN-1 exhibits a selectivity >130 fold over other K ⁺, Na ⁺, and Ca ²⁺ ion channels. Kv2.1-IN-1 decreases the apoptosis of HEK293 cells induced by H₂O₂. Kv2.1-IN-1 produces significant neuroprotection efficacy in middle cerebral artery occlusion (MCAO) rat. Kv2.1-IN-1 can be used for the study of ischemic stroke .

HY-148825

NP10679	iGluR Histamine Receptor Potassium Channel Cytochrome P450 Adrenergic Receptor	Metabolic Disease Inflammation/Immunology Cancer
NP10679 is a selective, pH dependent GluN2B subunit-specific N-methyl-D-aspartate (NMDA) receptor inhibitor with high oral bioavailability and good brain penetration. NP10679 inhibits GluN2B with IC₅₀s of 23 and 142 nM at pH 6.9 and 7.6, respectively. NP10679 is a histamine H1 antagonist and a hERG channel inhibitor with IC₅₀s of 73 and 620 nM, respectively. NP10679 is a reversible inhibitor of human liver CYP enzymes .

HY-14256

BMS-191095 1 Publications Verification	Potassium Channel	Cardiovascular Disease Neurological Disease
BMS-191095 is a selective activator of mitochondrial ATP-sensitive potassium (mitoKATP) channels. BMS-191095 inhibits human platelet aggregation by opening mitochondrial K(ATP) channels .

HY-149164

BTB09089 1 Publications Verification	GPR65	Neurological Disease Inflammation/Immunology
BTB09089 is a T cell death-associated gene 8 (TDAG8/GPR65) specific agonist. BTB09089 increases TDAG8 expression and regulates the cytokine production of T cells and macrophages .

HY-N0361

Dihydrocapsaicin 2 Publications Verification	TRP Channel Reactive Oxygen Species (ROS) Apoptosis Caspase Bcl-2 Family Akt PI3K	Cardiovascular Disease Neurological Disease
Dihydrocapsaicin, a capsaicin, is a potent and selective TRPV1 (transient receptor potential vanilloid channel 1) agonist. Dihydrocapsaicin reduces AIF, Bax, and Caspase-3 expressions, and increased Bcl-2, Bcl-xL and p-Akt levels. Dihydrocapsaicin enhances the hypothermia-induced neuroprotection following ischemic stroke via PI3K/Akt regulation in rat .

HY-N0361R

Dihydrocapsaicin (Standard)	Reference Standards TRP Channel Reactive Oxygen Species (ROS) Apoptosis Caspase Bcl-2 Family Akt PI3K	Cardiovascular Disease Neurological Disease
Dihydrocapsaicin (Standard) is the analytical standard of Dihydrocapsaicin. This product is intended for research and analytical applications. Dihydrocapsaicin, a capsaicin, is a potent and selective TRPV1 (transient receptor potential vanilloid channel 1) agonist. Dihydrocapsaicin reduces AIF, Bax, and Caspase-3 expressions, and increased Bcl-2, Bcl-xL and p-Akt levels. Dihydrocapsaicin enhances the hypothermia-induced neuroprotection following ischemic stroke via PI3K/Akt regulation in rat .

HY-157936

GluN2B-NMDAR antagonist-2	iGluR	Neurological Disease
GluN2B-NMDAR antagonist-2 (compound S-58) is a potent, selective and cross the blood-brain barrier NMDAR-GluN2B antagonist with an IC₅₀ value of 74.01, nM. GluN2B-NMDAR antagonist-2 shows mild cytotoxicity. GluN2B-NMDAR antagonist-2 decreases the cerebral infarction rates and neurologic deficit scores. GluN2B-NMDAR antagonist-2 has the potential for the research of stroke .

HY-N3847

Eriodictyol-7-O-glucoside Eriodictyol 7-O-β-D-glucoside	Keap1-Nrf2	Neurological Disease
Eriodictyol-7-O-glucoside (Eriodictyol 7-O-β-D-glucoside), a flavonoid, is an Nrf2 activator. Eriodictyol-7-O-glucoside exhibits significant scavenging effects on both hydroxyl radicals and superoxide anions, with IC₅₀ values of 0.28 mM and 0.30 mM, respectively. Eriodictyol-7-O-glucoside increases the nuclear localization of Nrf2 and induces the expression of the Nrf2/ARE-dependent genes. Eriodictyol-7-O-glucoside provides protection against oxygen and glucose deprivation (OGD)-induced oxidative insult. Eriodictyol-7-O-glucoside demonstrates neuroprotective efficacy in a rat model of focal cerebral ischemia (MCAO). Eriodictyol-7-O-glucoside can be used for the study of stroke .

HY-125039

N-Acetyl lysyltyrosylcysteine amide 2 Publications Verification	Glutathione Peroxidase	Cardiovascular Disease Neurological Disease
N-Acetyl lysyltyrosylcysteine amide is a potent, reversible, specific, and non-toxic tripeptide inhibitor of myeloperoxidase (MPO). N-Acetyl lysyltyrosylcysteine amide effectively inhibits MPO generation of toxic oxidants in vivo. N-Acetyl lysyltyrosylcysteine amide reduces neuronal damage and preserves brain tissue and neurological function in the stroked brain. N-Acetyl lysyltyrosylcysteine amide inhibits MPO-dependent hypochlorous acid (HOCl) generation, protein nitration, and LDL oxidation .

HY-17468A

Bumetanide sodium Ro 10-6338 sodium; PF 1593 sodium	NKCC	Cardiovascular Disease Metabolic Disease
Bumetanide sodium, a highly potent loop diuretic, is a Na ⁺-K ⁺-Cl ⁺ cotransporter (NKCC) blocker. Bumetanide sodium is a selective NKCC1 inhibitor, and also inhibits NKCC2, with IC₅₀s of 0.68 and 4.0 μM for hNKCC1A and hNKCC2A, respectively .

HY-17468

Bumetanide Maximum Cited Publications 14 Publications Verification Ro 10-6338; PF 1593	NKCC	Cardiovascular Disease Metabolic Disease
Bumetanide (Ro 10-6338; PF 1593), a highly potent loop diuretic, is a Na ⁺-K ⁺-Cl ⁺ cotransporter (NKCC) blocker. Bumetanide is a selective NKCC1 inhibitor, but also inhibits NKCC2, with IC₅₀s of 0.68 μM and 4.0 μM for hNKCC1A and hNKCC2A, respectively .

HY-N2255

Crebanine 3 Publications Verification	Akt Apoptosis NF-κB Reactive Oxygen Species (ROS) p38 MAPK ERK Interleukin Related TNF Receptor NO Synthase nAChR Bacterial	Infection Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
Crebanine is an isoquinoline-like alkaloid that can be derived from Stephania. Crebanine is an antagonist of the α7-nAChR with an IC₅₀ of 19.1 μM. Crebanine suppresses the proliferation, migration, and invasion of cancer cells, triggers reactive oxygen species (ROS) burst, and promotes apoptosis. Crebanine inhibits the AKT/FoxO3a, NF-κB and MAPK signaling pathways. Crebanine attenuates NOX2 hyperactivation, exhibits antioxidant properties by reducing reactive oxygen species and peroxidation. Crebanine inhibits voltage-dependent Na ⁺ current in guinea-pig ventricular myocytes. Crebanine has high inhibitory activity against gram-positive animal pathogenic bacteria. Crebanine ameliorates ischemia-reperfusion brain damage in middle cerebral artery occlusion and reperfusion (MCAO/R) rats. Crebanine significantly improves Scopolamine (HY-N0296)-induced cognitive deficits in ICR mice. Crebanine can be used for the study of hepatocellular carcinoma (HCC), cerebral ischemia and Alzheimer's disease .

HY-B0612AR

Lercanidipine hydrochloride (Standard)	Reference Standards Calcium Channel Apoptosis Reactive Oxygen Species (ROS) p38 MAPK NF-κB	Cardiovascular Disease Neurological Disease
Lercanidipine (hydrochloride) (Standard) is the analytical standard of Lercanidipine (hydrochloride). This product is intended for research and analytical applications. Lercanidipine is a third-generation, lipophilic, brain-penetrant, vascular-selective and orally active dihydropyridine-calcium channel blocker with a pIC₅₀ of 7.74 (converts from μM). Lercanidipine has long lasting antihypertensive action as well as reno- and neuro-protective effect. Lercanidipine also shows anti-oxidant, anti-inflammatory and anti-apoptotic properties. Lercanidipine can be used in cardiovascular and neurological research .

HY-B0612A

Lercanidipine hydrochloride 1 Publications Verification	Calcium Channel Apoptosis Reactive Oxygen Species (ROS) p38 MAPK NF-κB	Cardiovascular Disease Neurological Disease
Lercanidipine is a third-generation, lipophilic, brain-penetrant, vascular-selective and orally active dihydropyridine-calcium channel blocker with a pIC₅₀ of 7.74 (converts from μM). Lercanidipine has long lasting antihypertensive action as well as reno- and neuro-protective effect. Lercanidipine also shows anti-oxidant, anti-inflammatory and anti-apoptotic properties. Lercanidipine can be used in cardiovascular and neurological research .

HY-B0612

Lercanidipine 1 Publications Verification	Calcium Channel Apoptosis Reactive Oxygen Species (ROS) p38 MAPK NF-κB	Cardiovascular Disease Neurological Disease
Lercanidipine is a third-generation, lipophilic, brain-penetrant, vascular-selective and orally active dihydropyridine-calcium channel blocker with a pIC₅₀ of 7.74 (converts from μM). Lercanidipine has long lasting antihypertensive action as well as reno- and neuro-protective effect. Lercanidipine also shows anti-oxidant, anti-inflammatory and anti-apoptotic properties. Lercanidipine can be used in cardiovascular and neurological research .

HY-N0353R

Curdione (Standard) (+)-Curdione (Standard)	Reference Standards Ferroptosis Apoptosis Reactive Oxygen Species (ROS) Autophagy Glutathione Peroxidase Keap1-Nrf2 Heme Oxygenase (HO) TGF-β Receptor Indoleamine 2,3-Dioxygenase (IDO)	Others
Curdione (Standard) is the analytical standard of Curdione. This product is intended for research and analytical applications. Curdione ((+)-Curdione) is an orally active sesquiterpenoid. Curdione inhibits platelet aggregation. Curdione induces ferroptosis in colorectal cancer via m6A methylation mediated by METTL14 and YTHDF2. Curdione inhibits ferroptosis in Isoproterenol (HY-B0468)-induced myocardial infarction by regulating the Keap1/Trx1/GPX4 signaling pathway, suppressing oxidative stress (ROS) and apoptosis. Curdione ameliorates Doxorubicin (HY-15142)-induced cardiotoxicity by inhibiting oxidative stress (ROS) and activating the Nrf2/HO-1 pathway. Curdione ameliorates sepsis-induced lung injury by inhibiting platelet-mediated neutrophil extracellular trap formation. Curdione ameliorates Bleomycin (HY-17565A)-induced pulmonary fibrosis by inhibiting TGF-β-induced fibroblast-to-myofibroblast differentiation. Curdione exhibits neuroprotective effects against focal cerebral ischemia-reperfusion injury in rats. Curdione exerts antiproliferative effects against human uterine leiomyosarcoma by targeting IDO1. Curdione protects vascular endothelial cells and atherosclerosis by regulating DNMT1-mediated ERBB4 promoter methylation. Curdione inhibits inducible prostaglandin E2 production (IC₅₀ = 1.1 μM) and cyclooxygenase 2 expression .

HY-N0353

Curdione 1 Publications Verification (+)-Curdione	Ferroptosis Apoptosis Reactive Oxygen Species (ROS) Autophagy Glutathione Peroxidase Keap1-Nrf2 Heme Oxygenase (HO) TGF-β Receptor Indoleamine 2,3-Dioxygenase (IDO)	Cardiovascular Disease Neurological Disease Cancer
Curdione ((+)-Curdione) is an orally active sesquiterpenoid. Curdione inhibits platelet aggregation. Curdione induces ferroptosis in colorectal cancer via m6A methylation mediated by METTL14 and YTHDF2. Curdione inhibits ferroptosis in Isoproterenol (HY-B0468)-induced myocardial infarction by regulating the Keap1/Trx1/GPX4 signaling pathway, suppressing oxidative stress (ROS) and apoptosis. Curdione ameliorates Doxorubicin (HY-15142)-induced cardiotoxicity by inhibiting oxidative stress (ROS) and activating the Nrf2/HO-1 pathway. Curdione ameliorates sepsis-induced lung injury by inhibiting platelet-mediated neutrophil extracellular trap formation. Curdione ameliorates Bleomycin (HY-17565A)-induced pulmonary fibrosis by inhibiting TGF-β-induced fibroblast-to-myofibroblast differentiation. Curdione exhibits neuroprotective effects against focal cerebral ischemia-reperfusion injury in rats. Curdione exerts antiproliferative effects against human uterine leiomyosarcoma by targeting IDO1. Curdione protects vascular endothelial cells and atherosclerosis by regulating DNMT1-mediated ERBB4 promoter methylation. Curdione inhibits inducible prostaglandin E2 production (IC₅₀ = 1.1 μM) and cyclooxygenase 2 expression .

Cat. No.	Product Name	Target	Research Area